A Phase 1 Study of MOMA-313 Alone and With Olaparib in People With Advanced Prostate or Pancreatic Cancer

Full Title

A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors

Purpose

Researchers want to find the best doses of MOMA-313 alone and with olaparib in people with cancer. The people in this study have advanced castration-resistant prostate cancer (CRPC) or pancreatic cancer. CRPC is prostate cancer that has spread and keeps growing even in the absence of hormones. Their cancers also have a genetic change called HR deficiency.

MOMA-313 and olaparib are each taken orally (by mouth). If you join this study, you will take MOMA-313 alone or with olaparib.

Contact

For more information or to see if you can join this study, please call Dr. Wassim Abida’s office at 646-442-4633.